Alternative Data for Eyenovia
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | N/A | Sign up | Sign up | Sign up |
| Webpage traffic | 2,000 | Sign up | Sign up | Sign up |
| Employee Rating | 70 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | N/A | Sign up | Sign up | Sign up |
| Facebook Followers | 243 | Sign up | Sign up | Sign up |
| Instagram Followers | 1,079 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | N/A | Sign up | Sign up | Sign up |
| X Mentions | 28 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 32 | Sign up | Sign up | Sign up |
| Linkedin Employees | 14 | Sign up | Sign up | Sign up |
About Eyenovia
Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology.
| Price | $15.82 |
| Target Price | Sign up |
| Volume | 4,640,000 |
| Market Cap | $81M |
| Year Range | $10.38 - $15.82 |
| Dividend Yield | 0% |
| Analyst Rating | 0% buy |
| Industry | Biotechnology |
In the news
Pharmaceutical and Biotechnology Royalty Rates Agreements Report and Directory 2026: Insights Into 1,567 Licensing Transactions by Company A-Z, Therapeutic Area, Technology, Headline ValueMarch 12 - GlobeNewswire |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '25 | 28,000 | 3.1M | -3.1M | -20M | -19M | -1.591 |
| Q4 '24 | 28,000 | 3.1M | -3.1M | -20M | 0 | -3.689 |
| Q3 '24 | 1,600 | 130,000 | -130,000 | -7.9M | -7M | -0.110 |
| Q2 '24 | 23,000 | 780,000 | -760,000 | -11M | -10M | -0.210 |
| Q1 '24 | 5,000 | 340,000 | -330,000 | -11M | -10M | -0.230 |
Insider Transactions View All
| Rowe Michael M filed to buy 109,998 shares at $0.5. August 28 '24 |
| Rowe Michael M filed to buy 82,927 shares at $0.6. August 27 '24 |
| Grant Stuart M. filed to buy 10,914,153 shares at $0.7. July 3 '24 |
| Grant Stuart M. filed to buy 5,430,715 shares at $1. March 28 '24 |
| Grant Stuart M. filed to buy 5,330,715 shares at $1.2. March 20 '24 |
Similar companies
Read more about Eyenovia (EYEN) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Eyenovia
The Market Cap of Eyenovia is $81M.
Currently, the price of one share of Eyenovia stock is $15.82.
The EYEN stock price chart above provides a comprehensive visual representation of Eyenovia's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Eyenovia shares. Our platform offers an up-to-date EYEN stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Eyenovia (EYEN) does not offer dividends to its shareholders. Investors interested in Eyenovia should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Eyenovia are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
